ARCT holds up as Moderna and BioNTech shares pull back after Merck-Keytruda plus personalized mRNA melanoma results

Shares tied to mRNA cancer vaccine approaches traded unevenly after a positive late-stage update for a personalized vaccine strategy in melanoma, with one ticker cluster showing resilience even as other names reversed.

The rally around Moderna-linked trading began on Wednesday following news that Merck and Moderna reported favorable late-stage results for a personalized mRNA cancer vaccine used in combination with Keytruda, Merck’s immunotherapy for cancer. The update was described as occurring in a high-risk melanoma setting.

Despite the optimism around the Merck-Moderna combination, the market reaction was not uniform. The same report noted that shares of Moderna and BioNTech pulled back after the initial lift, underscoring how quickly investors can trim risk even when headlines are constructive.

Alongside those movements, the report highlighted that “ARCT” defied the broader mRNA selloff, extending the rally rather than following the apparent retreat in peer names. The post did not provide details about the specific catalysts behind ARCT’s relative strength beyond referencing the wider mRNA tape.

The personalized mRNA concept at the center of the update is intended to tailor vaccine instructions to an individual patient’s tumor features, with the goal of improving immune system targeting. Combining that approach with Keytruda aims to pair a vaccine-driven immune response with an established checkpoint pathway for cancer treatment.

Moderna’s role in the news was tied specifically to the late-stage personalized vaccine results alongside Merck, while BioNTech was referenced only in the context of stock-price movement rather than as a source of the clinical data in the cited post.

What was not disclosed in the post matters for interpreting the market reaction. The report did not outline trial endpoints, effect sizes, safety indicates, sample size, or timelines for regulatory submissions, and it did not attribute the post-Wednesday pullback in Moderna and BioNTech shares to any separate negative development.

Going forward, traders are likely to focus on whether future details from the late-stage program (such as how durable the response is, how benefit compares across patient subgroups, and what the safety profile looks like in high-risk melanoma) change the near-term narrative for personalized mRNA oncology. Additional clarification from the companies about timing and next-study plans would also be a key swing factor, especially if the stock-market reaction continues to diverge across the mRNA complex.